Zacks: Analysts Anticipate Apollo Endosurgery, Inc. (NASDAQ:APEN) Will Post Earnings of -$0.21 Per Share

Brokerages expect Apollo Endosurgery, Inc. (NASDAQ:APEN – Get Rating) to report ($0.21) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Apollo Endosurgery’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.24). Apollo Endosurgery reported earnings of ($0.11) per share during the same quarter last year, which would indicate a negative year over year growth rate of 90.9%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Apollo Endosurgery will report full year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.91) to ($0.61). For the next year, analysts expect that the business will post earnings of ($0.75) per share, with EPS estimates ranging from ($0.88) to ($0.48). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Apollo Endosurgery.

Apollo Endosurgery (NASDAQ:APEN – Get Rating) last posted its earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.21). Apollo Endosurgery had a negative net margin of 43.31% and a negative return on equity of 95.87%. The company had revenue of $16.66 million during the quarter, compared to analysts’ expectations of $15.69 million. During the same quarter last year, the company posted ($0.17) EPS.

Several brokerages have weighed in on APEN. Stifel Nicolaus dropped their price objective on shares of Apollo Endosurgery from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, February 23rd. Piper Sandler dropped their price objective on shares of Apollo Endosurgery from $14.00 to $12.00 in a research note on Wednesday, February 23rd. Finally, Zacks Investment Research upgraded shares of Apollo Endosurgery from a “sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.50.

Apollo Endosurgery stock traded up $0.20 during midday trading on Friday, hitting $4.67. The company’s stock had a trading volume of 57,475 shares, compared to its average volume of 177,180. Apollo Endosurgery has a 1-year low of $3.58 and a 1-year high of $10.39. The company has a debt-to-equity ratio of 0.97, a current ratio of 7.78 and a quick ratio of 6.83. The company has a 50-day moving average price of $5.34 and a two-hundred day moving average price of $6.43. The company has a market cap of $187.97 million, a price-to-earnings ratio of -5.70 and a beta of 2.26.

In other news, CFO Jeffrey G. Black bought 15,000 shares of the company’s stock in a transaction dated Monday, February 28th. The stock was bought at an average cost of $5.66 per share, for a total transaction of $84,900.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 30.00% of the stock is currently owned by insiders.

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE bought a new stake in shares of Apollo Endosurgery during the 4th quarter valued at approximately $41,000. Lazard Asset Management LLC grew its holdings in shares of Apollo Endosurgery by 57.2% during the 4th quarter. Lazard Asset Management LLC now owns 6,142 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 2,236 shares during the last quarter. Waypoint Capital Advisors LLC bought a new stake in shares of Apollo Endosurgery during the 1st quarter valued at approximately $58,000. Barclays PLC grew its holdings in shares of Apollo Endosurgery by 384.1% during the 3rd quarter. Barclays PLC now owns 6,772 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 5,373 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of Apollo Endosurgery during the 1st quarter valued at approximately $67,000. 94.64% of the stock is currently owned by institutional investors.

About Apollo Endosurgery (Get Rating)

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope.

Recommended Stories